A trial tested an enhanced recovery after surgery (ERAS) protocol in patients who underwent ambulatory transurethral resection (TURBT) of bladder cancer.
UConn Center on Aging researchers have published a new editorial in the journal Aging titled "Polyploidy-induced senescence: Linking development, differentiation, repair, and (possibly) cancer?" In ...
Investigators reported results from the first randomized controlled trial of office-based laser photocoagulation to standard TURBT for low-grade Ta bladder tumors.
Morning Overview on MSN
Bladder cancer warning signs you can’t ignore and how doctors treat it
Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...
Bacteria may be the next frontier in cancer treatment, according to a team led by researchers at Penn State that devised a new approach of creating bacteria-derived mixtures—or cocktails—to help fight ...
Researchers at the Icahn School of Medicine at Mount Sinai have reported promising findings that may help redefine treatment for patients with muscle-invasive bladder cancer, a potentially aggressive ...
June 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved UroGen Pharma's (UR8.F), opens new tab drug to treat a type of bladder cancer, providing an alternative treatment as ...
Urine for a breakthrough — in a true medical milestone, UCLA surgeons completed the world’s first in-human bladder transplant. Dr. Nima Nassiri, a urologic transplant surgeon and director of the UCLA ...
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results We conducted a prospective ...
Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...
Stocktwits on MSN
How high can IBRX stock go now? Here’s what Wall Street thinks after Saudi nod for bladder cancer filing
D. Boral Capital reiterated a ‘Buy’ rating and a $24 price target, implying nearly 300% upside from the stock's last close. ・Saudi regulators encouraged a filing for a bladder cancer therapy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results